SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

MapLight Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

Planning underway for ZEPHYR-2, the confirmatory Phase 3 trial of ML-007C-MA in schizophrenia, with

MPLT

Related stories